Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Celldex Therapeutics, Inc. reported revenue of $2M, down 78.0% year over year. Operating margin was -18599.8% and net margin -16748.0%, on a free-cash-flow margin of -13829.1% with capital expenditure at 175.7% of revenue. Every figure is computed directly from CLDX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $2M | -18599.8% | -16748.0% |
| FY2024 | $7M | -2778.9% | -2248.8% |
| FY2023 | $7M | -2245.3% | -2054.8% |
| FY2022 | $2M | -4889.0% | -4765.6% |
| FY2021 | $5M | -1531.8% | -1516.0% |
How does CLDX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.